Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. reports developments in its global, full-service clinical contract research organization business, providing Phase I-IV clinical development services to biotechnology, pharmaceutical and medical device companies. Company news centers on quarterly and annual operating results, conference-call announcements and performance measures used in the CRO model, including revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios.
Updates also describe Medpace's therapeutic and regulatory expertise across major development areas such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported robust financial results for Q1 2023, with revenue of $434.1 million, up 31.2% year-over-year. The company achieved a net book-to-bill ratio of 1.28x, with net new business awards of $555.8 million, a 31.4% increase. GAAP net income rose to $72.9 million or $2.27 per diluted share, compared to $61.3 million or $1.69 per diluted share last year. EBITDA increased 31.9% to $92.8 million, yielding an EBITDA margin of 21.4%. The company projects 2023 revenue between $1.745 billion and $1.805 billion, reflecting growth of 19.5% to 23.6%.
Cash flow from operations reached $80.1 million, with a remaining $332.7 million for share repurchase. Medpace will host a conference call on April 25, 2023, to further discuss these results.
Medpace Holdings (Nasdaq: MEDP) will report its Q1 2023 financial results on April 24, 2023, after market close. A conference call is scheduled for April 25, 2023, at 9:00 a.m. ET to discuss these results. Interested participants can register in advance through a provided link and are encouraged to join 10 minutes early. The call will also be accessible via webcast on Medpace's investor relations website, where a replay will be available afterwards. Additionally, a supplemental slide presentation will be posted on the site prior to the call.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 27.7% increase in fourth-quarter 2022 revenue, reaching $394.1 million, compared to $308.6 million in Q4 2021. The net income for Q4 2022 rose to $68.7 million or $2.12 per diluted share, up from $50.0 million or $1.32 per diluted share the previous year. Full-year 2022 revenue was $1,460.0 million, a 27.8% increase. The company forecasts 2023 revenue between $1.690 billion and $1.750 billion, implying growth of 15.8% to 19.9%.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its fourth quarter and fiscal year 2022 financial results on February 13, 2023, after market close. A conference call is scheduled for February 14, 2023, at 9:00 a.m. ET to discuss these results. Participants can register in advance through the provided link. The call will also be accessible via webcast on Medpace's investor website, with a replay available after the event. Medpace is a global clinical contract research organization offering comprehensive services across various therapeutic areas.